Generated by AI
Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases. The company’s current programs center on engineered induced pluripotent stem cells and induced mesenchymal stem cells designed to create off-the-shelf, allogeneic treatments that can be manufactured without patient-specific cell harvesting. Its pipeline includes preclinical product candidates aimed at ovarian cancer and rheumatoid arthritis, reflecting its emphasis on therapeutic areas with high unmet medical need. Ernexa Therapeutics Inc. works at the intersection of cell engineering, immunology, and regenerative medicine, using proprietary mRNA and gene-modification technologies to direct how cells behave and deliver targeted biological effects. Headquartered in Cambridge, Massachusetts, the company operates as a clinical-stage biotechnology developer with a focused role in the evolving market for next-generation cellular medicines.
Website1035 Cambridge Street
Cambridge, MA, 02141
United States
The latest articles about ERNA.
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET Register here CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today a
Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in HoustonCAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a
Summary of Sep 15's posts. Generated by AI.
Summary of Jul 15's posts. Generated by AI.
No summary yet.
Summary of May 7's posts. Generated by AI.
Investors talking about ERNA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.